Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Osilodrostat Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 10,750Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Recordati Announce Publication of Outcomes From PIII LINC 3 Study of Isturisa
    Recordati Announce Publication of Outcomes From PIII LINC 3 Study of Isturisa

    31 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220830005004/en

    BUSINESSWIRE
    31 Aug 2022
    Share Share
    Phase III LINC 3 Study Says ISTURISA Shows Improvement in Cushing’s Disease
    Phase III LINC 3 Study Says ISTURISA Shows Improvement in Cushing’s Disease

    13 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220513005219/en

    BUSINESSWIRE
    13 May 2022
    Share Share
    Recordati: Positive Results From the PH III LINC-3 Study of Isturisa®
    Recordati: Positive Results From the PH III LINC-3 Study of Isturisa®

    27 Jul 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200727005863/en

    BUSINESSWIRE
    27 Jul 2020
    Share Share
    Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial
    Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial

    17 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200617005250/en

    BUSINESSWIRE
    17 Jun 2020
    Share Share
    Recordati Rare Diseases now holds Isturisa® European MA
    Recordati Rare Diseases now holds Isturisa® European MA

    08 Apr 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/04/08/2013471/0/en/Recordati-Rare-Diseases-now-holds-Isturisa-European-MA.html

    GLOBENEWSWIRE
    08 Apr 2020
    Share Share